Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Mol Cancer Ther. 2019 Sep 5;18(11):1916–1925. doi: 10.1158/1535-7163.MCT-18-1334

Figure 2: RX-5902 treatment results in G2/M cell cycle arrest and apoptosis in sensitive cell lines.

Figure 2:

(A) Flow-cytometric analysis of cell-cycle distribution in two sensitive (MDA-MB-231 and HCT1806) and two resistant (MDA-MB-436 and CAL-120) cell lines exposed to RX-5902 for 24 hours. (B) Representative graphs for a sensitive (HCC1806) and a resistant (CAL-120) cell line treated with 100 nM RX-5902 or no drug control demonstrating cellular fractions in G1, G2/M and aneuploidy. (C) Indicated cell lines were treated with RX-5902 (0-100 nM) for 72 hours and apoptosis was assessed using the Incucyte Caspase 3/7 Green apoptosis assay with live cell microscopy. S; sensitive to RX-5902, R; resistant to RX-5902, ND; no drug control. *p<0.05, **p<0.01, ****p<0.0001,